New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 21, 2014
11:23 EDTECYTEndocyte price target raised to $41 from $21 at Brean Capital
Brean Capital raised its price target for Endocyte shares to $41 following the positive CHMP positive decision for vintafolide and the positive Phase 2 trial results. The firm keeps a Buy rating on the stock.
News For ECYT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 30, 2014
10:02 EDTECYTOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
05:28 EDTECYTEndocyte downgraded to Hold from Buy at Brean Capital
Brean Capital downgraded Endocyte to Hold saying it views the company's data for vintafolide as "marginal."
September 29, 2014
06:27 EDTECYTEndocyte to host conference call
Subscribe for More Information
September 28, 2014
14:12 EDTECYTEndocyte says Phase 2b TARGET trial results show improved survival
Endocyte announced that the small molecule drug conjugate, SMDC, vintafolide in combination with docetaxel extended overall survival for patients with folate receptor positive recurrent non-small cell lung cancer, NSCLC, compared to patients receiving monotherapy docetaxel in its TARGET Phase 2b clinical trial. The late-breaking TARGET trial data will be presented today at the European Society for Medical Oncology Congress, ESMO, by Rohit Lal, M.D., consultant medical oncologist at Guys and St Thomas' Hospital and an Honorary Consultant Medical Oncologist for Kings College Hospital, London.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use